(Total Views: 844)
Posted On: 03/17/2020 1:34:25 PM
Post# of 154619
“As soon as those doctors report that those patients are not needing ventilators or being taken off ventilators, the PR will be picked up world wide.”
One of my duties on this board (self appointed) is to war game scenarios and there is one issue with your scenarios, an issue that the FDA addressed with the IND trial protocol: placebo arm. We don’t have all the data, but it’s safe to assume that not every patient who goes on a ventilator for COVID19 will die. So simply saying leronlimab is successful in treating symptoms of the virus because 1 patient didn’t need a ventilator or discontinued use of a ventilator would be incorrect.
In addition, I don’t think the FDA will allow CYDY to publish a PR or allow NP to go on video saying the first patient on leronlimab survived COVID19 because at that point it would be hard to prove survival was the result of treatment without a placebo arm. But I do think that if a seriously ill patient does survive with treatment, word will spread to other doctors and hospitals and the trial will fill quickly.
One of my duties on this board (self appointed) is to war game scenarios and there is one issue with your scenarios, an issue that the FDA addressed with the IND trial protocol: placebo arm. We don’t have all the data, but it’s safe to assume that not every patient who goes on a ventilator for COVID19 will die. So simply saying leronlimab is successful in treating symptoms of the virus because 1 patient didn’t need a ventilator or discontinued use of a ventilator would be incorrect.
In addition, I don’t think the FDA will allow CYDY to publish a PR or allow NP to go on video saying the first patient on leronlimab survived COVID19 because at that point it would be hard to prove survival was the result of treatment without a placebo arm. But I do think that if a seriously ill patient does survive with treatment, word will spread to other doctors and hospitals and the trial will fill quickly.
(1)
(0)
